4DX.AX stock jumped 8.40% to A$4.00 on 27 Feb 2026 as investors positioned ahead of an imminent earnings update. The move came on 22,604,962.00 shares traded and lifted the year range after recent strength. Earnings are due around 27 Feb 2026 and the company’s revenue and guidance will be the key near-term catalysts for investors in Australia’s ASX-listed 4DMedical Limited.

4DX.AX stock: Earnings timing and what to watch

Earnings are scheduled for 27 Feb 2026 and market focus will be on revenue scale and margin progress. Expect commentary on XV Technology commercial uptake and any subscription growth in the XV lung ventilation analysis software. Management guidance and US reimbursement or pilot program updates would be immediate price drivers for 4DX.AX stock.

Price action and trading facts behind the move

The share price opened at A$3.68 and hit a high of A$4.09 before settling at A$4.00 on the close. Volume of 22,604,962.00 versus an average of 6,094,649.00 shows above-normal interest. The market cap is A$2,128,550,520.00, spotlighting a high valuation versus current revenues ahead of earnings.

Financials and valuation snapshot for 4DMedical Limited (4DX.AX)

Trailing twelve month revenue was A$5.85M with net loss A$30.07M and EPS -0.14. Key ratios include PE -26.57, PB 23.77, and price-to-sales roughly 486.60, signifying a growth story priced well above current sales. The balance sheet shows A$6.88M cash and A$4.31M debt with a working capital shortfall and current ratio 0.89.

Technical read and short-term setup for 4DX.AX stock

Momentum indicators are neutral to mildly constructive: RSI 50.30, MACD slightly positive, and Bollinger middle at A$3.59. The 50-day average is A$3.84 and 200-day average A$1.74, which shows recent strength over the longer trend. Traders will watch A$3.63 support and A$4.12 resistance intraday near the upper band.

Meyka AI rating, forecast and analyst context

Meyka AI rates 4DX.AX with a score out of 100. Meyka AI rates 4DX.AX with a score out of 100: 64.35 / 100 (Grade B, HOLD). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a 12-month price of A$4.12, a quarterly target of A$5.04, and a monthly level of A$3.33. The one-year projection implies an upside of 3.00% versus the close of A$4.00; forecasts are model-based projections and not guarantees.

Risks and catalysts ahead of the earnings report

Primary risks are continued cash burn, limited current revenue base, and high valuation metrics relative to peers in Medical – Devices. Catalysts include clearer SaaS subscription growth, regulatory or reimbursement wins in the US, and any reduction in operating losses. Watch guidance language and updated cash runway statements at the earnings release.

Final Thoughts

4DX.AX stock closed at A$4.00 on 27 Feb 2026 after a 8.40% intraday gain as the market priced in the upcoming earnings report. The company shows revenue growth but remains loss-making with EPS -0.14 and elevated valuation multiples such as PB 23.77 and PS roughly 486.60. Meyka AI’s forecast model projects a 12-month price of A$4.12, implying an upside of 3.00% from today’s close versus a quarterly scenario at A$5.04 that implies 26.00% upside if execution accelerates. Investors should weigh the science-led growth case for 4DMedical Limited against cash burn and stretched valuations. For active traders, short-term technical levels near A$3.63 support and A$4.12 resistance will matter; for longer-term investors, the earnings commentary on commercial traction and contracts will be decisive. Use Meyka AI as an AI-powered market analysis platform for follow-up data and check the company statement and filings after the ASX close for confirmed figures.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.